Post COVID-19 economic recovery: Lessons from China's re-activation

Investors must focus not just on when economies are set to reopen, but when and how consumers and businesses will feel safe resuming normal activities.

04 May 2020


Post COVID-19 economic recovery: Lessons from China's re-activation

  • Investors must focus not just on when economies are set to reopen, but when and how consumers and businesses will feel safe resuming normal activities.
  • We examine the experience in China, where discretionary consumption is recovering slowly as individuals change behaviors to reduce risk of infection.
  • Developed economies are likely to face more difficulty normalizing than China or other North Asian countries, as there may be less individual acceptance of tracing and surveillance.
  • We suspect the outlook for risk assets will become more challenging from here, as investors must price in greater uncertainty and solvency risks on the recovery path.
  • Regionally, we prefer North Asian equities and credit given advantages in containing the virus.

Post COVID-19 economic recovery

China as a barometer for reactivation of Europe and US

Across the world, investors and non-investors alike are focused on when and how economies will 'reopen,' after COVID-19 related shutdowns. But just as important, if not more so, is when will economies 'reactivate?' In other words, when and how do consumers feel safe enough to resume normal spending behaviors? When will businesses feel they have created a safe enough environment to bring back workers and resume pre-crisis levels of production? It is well understood that a widely available vaccine is still several quarters away. It is also broadly agreed that a reduction in social distancing policies risks second waves of infections and potentially renewed shutdowns.

Therefore, in addition to the tendency for consumers and businesses to be cautious in the aftermath of a recession, we have to monitor behavioral changes based on lingering fears of further virus spread.

In attempting to examine potential post-virus behavioral changes, we think it most useful to look at China as a leading indicator for Europe and the US. China is a useful barometer given it is a country that experienced a severe bout of the virus but is now roughly two months into its 'reopening.' There are of course major differences across countries, given varying levels of severity of the virus, significant variation in public health infrastructure including testing and contact tracing, diverse macro policy responses, unique reopening strategies along with political and cultural differences. So we have to be cautious in drawing definitive conclusions from China's experience for western democracies. Still, we'd argue that the basic contours of human behavior are the same across regions, and that Chinese consumer and business behaviors post-reopening can provide important clues as to how things will look in the west. 

China's reopening

China's strategy for containing the virus involved a nearly two- month-long lockdown of Hubei, the epicenter of the COVID-19 outbreak in China, which ended on March 25. Outside Hubei, Chinese local officials began opening up their economies two to three weeks after the extended Chinese New Year's holiday ended on February 3. The real catalyst came during the February 21 Politburo meeting, where the central government pushed hard for work resumption while remaining committed to containing any second waves. This required a strong contact tracing system, surveillance, temperature checking and some travel quarantining requirements. As an example, China mandates that individuals have barcodes on their phones signaling their relative health risk to others before accessing public transportation or entering buildings. Potentially contagious individuals face a mandated quarantine if they are deemed high risk to others. While there have been small outbreaks of the virus in particular localities, most seem to be imported from other countries. In response, China has sharply reduced international travel and mandated strict quarantine guidelines for incoming travelers.

Exhibit 1: Daily new infections/million pop. in China

Post COVID-19 economic recovery

Current activities in China are still somewhat subdued

Given the challenge of reopening the economy while making sure the virus is contained, the slope of economic activity was inevitably flat at the very beginning and gradually moved higher as the government and the public gained more confidence in health conditions. The signs of an acceleration of daily activities as measured in coal consumption, property sales and city traffic congestion levels are visible around late February and early March, following the aforementioned Politburo meeting on February 21. But two months in, current levels of activity are still somewhat subdued from previous years.

Exhibit 2: Coal consumption of 6 largest power groups

Exhibit 3: 100-city traffic congestion index (7-day ma)

Our colleagues in China do note a change in much of the public's daily routines. Ridership of city public transport has remained far below pre-outbreak levels, with many preferring to drive to work. Indeed, city traffic congestion has almost returned to pre-outbreak levels, and during peak hours is particularly congested. But the length of such peak hours has shrunk, as individuals choose to return home from city centers as opposed to staying out for leisure purposes.

Exhibit 4: Chinese consumption demand recovery lags supply

Indeed, while China has largely returned to work, the country has yet to return to spending in earnest. Overall discretionary consumption was down 20% from last year.1 To be sure, much of this is due to the decline in real disposable income by 3.9% YoY in 1Q, the sharpest fall since data became available in 2002, as well as uncertainty about the future

But there is also a general desire to avoid crowds which has led to a slow recovery in discretionary spending. Shopping malls are open but are much less populated as people have chosen to avoid gathering. Dining out at restaurants is still a fraction of what it was pre-pandemic as is spending on in-store services like beauty salons. There has been a move away from offline towards online spending, with the former down 13%YoY and the latter up 11%YoY in March, according to official data. These fail to offset though because offline consumption is still roughly three-fourths of consumer spending. Exhibit 4 displays current and predicted activity levels across various areas of the economy, showing that while the supply side is mostly up and running, various areas of demand will take longer to normalize.

A recent paper from the National University of Singapore2 has used high frequency data to track offline spending in China. The authors find that consumption patterns show a strong negative relationship to the severity of the health crisis, even accounting for distancing and mobility restrictions. Specifically, when the one-day lagged number of new cases rises, day-to-day consumption declines, and vice versa. This includes data in the first half of April, when most mobility restrictions had been relaxed and concerns grew over potential second waves of infections (either from imported or asymptomatic cases, which the government started to report at the beginning of April). The authors attribute much of the decline in consumption to uncertainty around the disease itself, suggesting that the more that can be done to manage the public health crisis and make people feel safe, the more genuine a recovery in normal consumption behavior will occur.

Exhibit 5: Supply outpacing domestic demand in China

Source: NBS, UBS Asset Management, data as of 31 March 2020.

Early lessons from China's experience

One takeaway is that there will likely be a very hesitant and gradual recovery in developed economies

China's approximately two-month re-opening process offers some guidance on what developed economies should expect. One takeaway is that there will likely be a very hesitant and gradual recovery in developed economies. Just because a business has reopened, it does not mean consumers will flock to it if they generally want to stay out of crowded places. A related and logical conclusion is that the safer people feel, whether that is due to low case growth nearby or trust in the public health infrastructure, the more likely they are to resume semi-normal activities.

There are of course reasons to expect a less successful return to normal in developed economies than China's experience. The US and Europe have undergone much more severe outbreaks and longer plateaus of new case growth before declining. While contact tracing and surveillance tools are in development, participation is likely to be voluntary as opposed to mandatory in most situations. And unemployment rates, in the US in particular, are skyrocketing relative to China's. This means a slower reunion of workers and employers as well as a more cautious consumer.

Post COVID-19 economic recovery

Market outlook: caution is warranted on risk assets

The above suggests caution is warranted on risk assets as global equity markets appear to be pricing in a swifter recovery with more certainty than is likely, given China's experience and differences from western economies. The S&P 500 is only down about 10% for 2020 which is quite remarkable given the sharp decline in the growth outlook and lofty valuations entering the year. As discussed in the April Macro Monthly, we have tremendous respect for the power of coordinated monetary and fiscal policy in providing a bridge through what will be a bumpy road for developed economies. But we would argue that policy support is largely priced in, and that current valuations do not adequately embed the meaningful uncertainty around growth and earnings over coming quarters and years. Indeed, while policymakers have helped provide liquidity where needed, they have not erased solvency risk. Credit and equity performance is likely to be more sideways as markets grapple with the risks of a much more difficult road to recovery, including potential for second waves of COVID-19. We have moved tactically underweight global equities after the recent rally.

Within equity markets, the rebound has been driven by defensives and growth stocks – which is not part of the typical recovery playbook but understandable given the prolonged uncertainties we face. Valuation spreads between cyclicals and defensives are at extremes and will eventually snap back. We would expect this to occur in anticipation of a normalization in global spending patterns – which may require greater visibility on a vaccine. For now we favor a moderately defensive equity allocation which should include sectors that are less impacted from lockdowns such as communication services or health care in the current environment. As the road to recovery becomes clearer, we would expect the most sold-off sectors (e.g., automobiles, banks, energy) to bottom from an absolute point of view given they trade at deep recession prices and should eventually recover. Therefore, for investors with a longer time horizon and ample risk tolerance we believe that buying into those sectors on dips is likely to pay off.

We prefer China and other North Asia economies over their EM counterparts as the former have shown greater ability to manage the health crisis and control the outbreak. At the same time, markets like Korea, Taiwan and Mainland China are less vulnerable from an external financing point of view and have more room for policy action. We are expressing this view across equities and fixed income, the latter reflected in a preference for Asian high yield relative to broader emerging market debt. Over time, we expect the overvalued USD to weaken and gold to rally given extraordinary monetary and fiscal stimulus in the US.

Asset class attractiveness

The chart below shows the views of our Macro Asset Allocation Strategy team on overall asset class attractiveness, as well as the relative attractiveness within equities, fixed income and currencies, as of 30 April 2020.

More insights

Singapore Retail Investors


This website is not intended for and should not be accessed by persons located or resident in any jurisdiction where (by reason of that person's nationality, domicile, residence or otherwise) the publication or availability of this website is prohibited or contrary to local law or regulation or would subject any UBS entity to any registration or licensing requirements in such jurisdictions. It is your responsibility to be aware of, to obtain all relevant regulatory approvals, licenses, verifications and/or registrations under, and to observe all applicable laws and regulations of any relevant jurisdiction in connection with your entrance to this website. Each investment product and service referred to on this website is intended to be made available only to residents in Singapore.

UBS reserves the right to change, modify, add or remove content on the website as well as these terms at any time for any reason without notice. Such changes shall be effective immediately upon posting. You acknowledge that by accessing our website after we have posted changes to these terms, you are agreeing to these terms as modified.

The materials on this Website are distributed by UBS Asset Management (Singapore) Ltd (company registration number: 199308367C), which is licensed by Monetary Authority of Singapore ("MAS") in Singapore pursuant to the Securities and Futures Act (Chapter 289 of Singapore). UBS Asset Management (Singapore) Ltd is part of the Asset Management business division of UBS Group AG. UBS Asset Management (Singapore) Ltd together with UBS Group AG and its group companies shall collectively be referred to as "UBS".

The information contained in this Website has been prepared and is intended for general circulation. The information does not constitute advice and does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. The investment services or products referred to in this Website may not be suitable for all investors. UBS recommends that you independently evaluate particular investments and strategies and seek independent advice from a financial adviser regarding the suitability of such investment products, taking into account your specific investment objectives, financial situation and particular needs, before making a commitment to purchase any investment products. Investment involves risks. You should be aware that investments may increase or decrease in value and that past performance is not indicative of future performance.

The information contained in this Website is not an offer to buy or sell or the solicitation of an offer to buy or sell any investment product or to participate in any particular trading strategy. UBS, its officers and/or employees may have interests in any of the investment products referred to on this Website by acting in various roles. UBS, its officers and/or employees may receive fees, commissions or other benefits for acting in those capacities. In addition, UBS, its officers and/or employees may buy or sell investment products as principal or agent and may effect transactions which are not consistent with the information set out in this Website.

You fully understand and agree that, by making available this Website, UBS should not be construed as making: (a) any endorsement of any investment product referred to in this Website; (b) any representation that UBS has performed any due diligence on any investment product referred to in this Website; or (c) any representation that the information in this Website is complete, accurate, clear, fair and not misleading. The use or reliance on any such information contained in this Website is at your own risk and any losses which may be suffered as a result of you entering into any investment are for your account and UBS shall not be liable for any losses arising from or incurred by you in connection therewith. UBS is not responsible or liable for the accuracy and completeness of any such information or the performance or outcome of any investment made by you after receipt of such information, irrespective of whether such information was provided at your request.

Using, copying, redistributing or republishing any part of this Website without prior written permission from UBS is prohibited. Any statements made regarding investment performance objectives, risk and/or return targets shall not constitute a representation or warranty that such objectives or expectations will be achieved or risks are fully disclosed. The information and opinions contained in this Website is based upon information obtained from sources believed to be reliable and in good faith but no responsibility is accepted for any misrepresentation, errors or omissions. All such information and opinions are subject to change without notice. A number of comments in this Website are based on current expectations and are considered “forward-looking statements”. Actual future results may prove to be different from expectations and any unforeseen risk or event may arise in the future. The opinions expressed are a reflection of UBS’s judgment at the time this document is compiled and any obligation to update or alter forward-looking statements as a result of new information, future events, or otherwise is disclaimed.

UBS does not hold out any of its officers and/or employees as having any authority to advise you, and UBS does not purport to advise you on any investment product. Any investment will be made at your sole risk and UBS is not and shall not, in any manner, be liable or responsible for the consequences of any investment.

This Website and its contents are provided on an “as is” and “as available” basis. UBS does not warrant: (a) the accuracy, timeliness, adequacy commercial value or completeness of this Website or its contents, and expressly disclaims any liability for errors, delays or omissions in the contents, or for any action taken in reliance on the contents; (b) that your use of and/or access to this Website or its contents, will be uninterrupted, timely, secure or free from errors or that any identified defect will be corrected; (c) that this Website or any content will meet your requirements or are free from any virus or other malicious, destructive or corrupting code, agent, program or macros; (d) that any information, instructions or communications posted or transmitted by you through this Website is secure and cannot be accessed by unauthorised third parties; and (e) that use of the contents in this Website by you will not infringe the rights of any third parties. No warranty of any kind, implied, express or statutory, including but not limited to the warranties of non-infringement of third party rights, title, merchantability, satisfactory quality or fitness for a particular purpose and freedom from computer virus or other malicious, destructive or corrupting code, agent, program or macros, is given in conjunction with this Website.

You hereby agree to indemnify UBS and any of its officers, employees or agents against, and to keep UBS and any of its officers, employees or agents harmless from, any claims (actual and threatened), settlement sums, liability, loss, damages, costs (including solicitor and client costs and expenses (legal or otherwise)), charges, expenses, actions, proceedings, whether foreseeable or not which we may sustain, suffer or incur, directly or indirectly out of or in the course of or in connection with any the following: (a) any use of this Website or the contents by you, or any part thereof; (b) UBS having made available the Website; (c) any breach of these Terms by you, however arising; or (d) any negligence, act or omission, wilful default, unlawful act, fraud and/or misconduct on your part or violation of any rights of another person or entity by you.

The funds referred to in this Website have been authorised or recognised by the MAS for sale to the public in Singapore (the “Funds”). Copies of the registered Singapore prospectuses ("Prospectuses") referred to in this Website have been lodged with and registered by the MAS. The MAS assumes no responsibility for the contents of the Prospectuses. The registration of the Prospectuses by the MAS does not imply that the SFA or any other legal or regulatory requirements have been complied with.

MAS registration is not a recommendation or endorsement of a Fund nor does it guarantee the commercial merits or performance of such Fund. It does not mean that a Fund is suitable for all investors nor is it an endorsement of its suitability for any particular investor or class of investors. UBS Asset Management (Singapore) Ltd has been appointed as the representative for the Funds in Singapore for the purposes of performing administrative and other related functions relating to the offer of Shares under Section 287 of the Securities and Futures Act, Chapter 289 of Singapore (the "SFA") and such other functions as the MAS may prescribe.

You may not assign your rights under the Terms without our prior written consent. UBS Asset Management (Singapore) Ltd may assign our rights under the Terms to any third party.

No person or entity who is not a party to the Terms shall have any right under the Contracts (Rights of Third Parties) Act, Chapter 53B of Singapore or other similar laws to enforce any term of the Terms regardless of whether such person or entity has been identified by name, as a member of a class or as answering a particular description. For the avoidance of doubt, this shall not affect the rights of any permitted assignee or transferee of the Terms.

These Terms shall be governed by, and shall be construed in accordance with, the laws of Singapore. The courts of Singapore shall have exclusive jurisdiction to hear and determine any suit, action or proceeding, and to settle any disputes, which may arise out of or in connection with these Terms and, for such purposes, you agree to submit  to the jurisdiction of the courts of Singapore. Each party hereby waives any objection which it might at any time have to the courts of Singapore being nominated as the forum to hear and determine any proceedings and to settle any disputes and agrees not to claim that the courts of Singapore are not a convenient or appropriate forum.

© UBS 2021 - the key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.